Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Marinela Capanu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4953-3193; OpenAlex author ID A5045756365; NIH RePORTER profile ID 8795308. Sources: OpenAlex.

Their work

Papers
23
Trials
0
Grants
1
Labs led
0
Collaborators
80
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 4 papers · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 4 papers · 2026: 3 papers, 1 grant

Papers 23

  1. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  2. POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer Co-author DOI 10.64898/2026.03.15.711961↗
  3. Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancer Co-author DOI 10.64898/2026.09.17.752426↗
  4. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Co-author DOI 10.1038/s41591-024-03362-3↗
  5. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
  6. Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf139↗
  7. The Evolutionary Forest of Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-23-1541↗
  8. Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication. Co-author DOI 10.1016/j.pan.2024.05.515↗
  9. Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease. Co-author DOI 10.1093/jnci/djae095↗
  10. Pancreatic cancer: Cutaneous metastases, clinical descriptors and outcomes. Co-author DOI 10.1002/cam4.4916↗
  11. Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. Co-author DOI 10.1002/cncr.34269↗
  12. Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s40291-022-00614-1↗
  13. Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. Co-author DOI 10.1007/s00261-020-02726-w↗
  14. Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08123-w↗
  15. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.33038↗
  16. Detection of recurrent pancreatic cancer: value of second-opinion interpretations of cross-sectional images by subspecialized radiologists. Co-author DOI 10.1007/s00261-018-1765-z↗
  17. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adeno… Co-author DOI 10.1002/cncr.31218↗
  18. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Co-author DOI 10.1158/1078-0432.ccr-17-3099↗
  19. Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior. Co-author DOI 10.1186/s12885-018-4679-9↗
  20. Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers10120467↗
  21. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.30897↗
  22. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Co-author DOI 10.1002/cncr.26600↗
  23. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Co-author DOI 10.1097/coc.0b013e3181e84b1f↗

Grants 1

  1. Biostatistics Core P50CA257881↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 20 shared papers, 1 shared grant, 2011–2026 · strength 3.07
  2. Kenneth H. Yu · 14 shared papers, 2017–2026 · strength 1.83
  3. Christine A. Iacobuzio–Donahue · 7 shared papers, 1 shared grant, 2018–2026 · strength 1.70
  4. Wungki Park · 10 shared papers, 2020–2026 · strength 1.57
  5. Alice Chia-Chi Wei · 5 shared papers, 1 shared grant, 2024–2026 · strength 1.56
  6. Vinod P. Balachandran · 6 shared papers, 1 shared grant, 2019–2026 · strength 1.49
  7. Anna M. Varghese · 10 shared papers, 2018–2026 · strength 1.45
  8. Olca Baştürk · 4 shared papers, 1 shared grant, 2021–2026 · strength 1.35
  9. Fiyinfolu O. Balogun · 6 shared papers, 2024–2026 · strength 1.07
  10. Fergus Keane · 5 shared papers, 2024–2026 · strength 0.89
  11. David Paul Kelsen · 9 shared papers, 2011–2025 · strength 0.79
  12. Jason Stuart Lewis · 1 shared grant, 2026 · strength 0.67
  13. Caitlin A. McIntyre · 4 shared papers, 2020–2026 · strength 0.57
  14. Kevin C. Soares · 3 shared papers, 2025–2026 · strength 0.54
  15. William R. Jarnagin · 4 shared papers, 2020–2025 · strength 0.53
  16. Darren Cowzer · 3 shared papers, 2024–2025 · strength 0.53
  17. Anupriya Singhal · 3 shared papers, 2024–2025 · strength 0.53
  18. Zsofia Kinga Stadler · 4 shared papers, 2018–2025 · strength 0.42
  19. Akimasa Hayashi · 2 shared papers, 2025–2026 · strength 0.38
  20. Haochen Zhang · 2 shared papers, 2025–2026 · strength 0.38
  21. Benjamin D. Greenbaum · 2 shared papers, 2026 · strength 0.37
  22. Dana Pe'er · 2 shared papers, 2026 · strength 0.37
  23. Benoı̂t Rousseau · 2 shared papers, 2026 · strength 0.37
  24. Marc Hilmi · 2 shared papers, 2026 · strength 0.37
  25. Nuray Tezcan · 2 shared papers, 2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.